Figure 5 | Scientific Reports

Figure 5

From: Active ingredients Isorhamnetin of Croci Srigma inhibit stomach adenocarcinomas progression by MAPK/mTOR signaling pathway

Figure 5The alternative text for this image may have been generated using AI.

IH inhibits the proliferation and survival of HGC-27 cells. (A) Proliferation of IH-treated HGC-27 cells examined by RTCA. (B) Proliferation of IH-treated HGC-27 cells examined by CCK8. (C) Proliferation of IH-treated AGS cells examined by RTCA. (D) Apoptosis of IH-treated HGC-27 cells assayed by Annexin-V/APC staining. (E) Percentage of Annexin V + cells in IH-treated HGC-27 cells. (F) Apoptosis of IH-treated AGS cells assayed by Annexin-V/APC staining (up); Percentage of Annexin V + cells in IH-treated AGS cells (down). (G) Apoptosis of IH-treated GES-1 cells assayed by Annexin-V/APC staining. (H) Percentage of Annexin V + cells in IH-treated GES-1 cells. (I) Proliferation of IH-treated GES-1 cells examined by CCK8. Values are mean ± SD, n = 3, *P < 0.05, **P < 0.01 vs. control.

Back to article page